Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

A medical expert emphasized the critical need for the establishment of national guidelines and screening strategies especially for lung cancer tailored to Filipinos’ unique epidemiological landscape.

NDAQ:AZN) AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...

Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The stock has shown ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

UK’s former vaccine tsar says immunocompromised people were ‘de-prioritised’ in a ‘two-tier’ therapeutic rollout strategy ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...